Invivyd (IVVD) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Invivyd (IVVD) over the past year, losing 27.1% versus a loss of 57.3%. Over five years, KROS leads with a -70.1% price change compared with -97.8% for IVVD. Keros Therapeutics is the larger company by market cap ($230.8 million vs $206.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | KROS |
|---|---|---|
| Share price | $0.7004 | $11.64 |
| Market cap | $206.45M | $230.79M |
| 1-day change | -3.87% | +3.84% |
| YTD return | -71.64% | -42.83% |
| 1-year return | -57.29% | -27.07% |
| 5-year return | -97.84% | -70.15% |
| EPS (TTM) | $-0.33 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $22.55 |
| 52-week low | $0.528 | $9.69 |
| Distance from 52-week high | -77.19% | -48.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1327.76% | +70.36% |
| Average volume | 4.78M | 196.01K |
| Shares outstanding | 294.76M | 19.83M |
| Employees | 122 | 92 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed IVVD by 30.2 percentage points over the past year.
- The two companies sit in different sectors: Invivyd in Healthcare and Keros Therapeutics in Health Care.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
IVVD vs KROS FAQ
Which is bigger, Invivyd or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $206.45M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or KROS?
KROS returned -27.07% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Keros Therapeutics in the same industry?
No. Invivyd is in the Healthcare sector, while Keros Therapeutics is in Health Care.